Famciclovir, from the bench to the patient - a comprehensive review of preclinical data

International Journal of Antimicrobial Agents

Volumn 7, Issue 2, 1996, Pages 119-134

  Bacon, Teresa H ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Aciclovir; Famciclovir; Penciclovir; Preclinical; Valaciclovir

Indexed keywords

ACICLOVIR; DNA POLYMERASE; FAMCICLOVIR; PENCICLOVIR; VALACICLOVIR;

ANTIVIRAL ACTIVITY; BIOAVAILABILITY; CELL CULTURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW;

EID: 0030199335     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/0924-8579(96)00303-2     Document Type: Article

References (98)

1. [1] Vere Hodge RA, Sutton D, Boyd MR et al. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; penciclovir]. Antimicrob Agents Chemother 1989;33:1765-1773.
2. [2] Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antiviral Chem Chemother 1993;4(suppl 1):47-55.
3. [3] Whitley RJ, Gnann JW. Acyclovir: a decade later. N Engl J Med 1992;327:782-789.
4. [4] Beauchamp LM, Orr GF, de Miranda P et al. Amino acid ester prodrugs of acyclovir. Antiviral Chem Chemother 1992;3: 157-164.
5. [5] Boyd MR, Boon R, Fowles SE et al. Some biological properties of BRL 42810, a well absorbed oral prodrug of the antiherpes agent BRL 39123. Antiviral Res, 1988;9:146, abstract II-38.
6. [6] Clarke SE, Harrell AW, Chenery RJ. The role of aldehyde oxidase in the biotransformation of famciclovir to penciclovir as determined by a human in vitro system. Proc 5th Eur Int Soc Study Xenobiotics, Tours, France, 1993;3:61.
7. 13C NMR to identify the chiral monoacetylated intermediates in the conversion of famciclovir to penciclovir by human intestinal wall extract. Chirality 1993;5:577-582.
8. 14C-famciclovir to healthy subjects. Xenobiotica 1994;24:357-368.
9. [9] Pue MA, Pratt SK, Fairless AJ et al. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J Antimicrob Chemother 1994;33:119-127.
10. [10] Fowles SE, Fairless AJ, Pierce DM et al. A further study of the effect of food on the bioavailability and pharmacokinetics of penciclovir after oral administration of famciclovir. Br J Clin Pharmacol 1991;32:657P.
11. [11] Weller S, Blum MR, Doucette M et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single-and multiple-dose administration to normal volunteers. Clin Pharm Ther 1993;54:595-605.
12. [12] de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 1983;1(suppl B):29-37.
13. [13] Wilson CG, Washington N, Hardy JG et al. The influence of food on the absorption of acyclovir: a pharmacokinetic and scintigraphic assessment. Int J Pharm 1987;38:221-225.
14. [14] de Miranda P, Good SS. Species differences in the metabolism and disposition of antiviral nucleoside analogues: 1. Acyclovir. Antiviral Chem Chemother 1992;3:1-8.
15. [15] de Miranda P, Good SS, Laskin OL et al. Disposition of intravenous radioactive acyclovir. Clin Pharmacol Ther 1981;30: 662-672.
16. [16] Burnette TC, Harrington JA, Reardon JE et al. Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of acyclovir. J Biol Chem 1995;270:15 827-15 831.
17. [17] Crooks RJ, Murray A. Valaciclovir - a review of a promising new antiherpes agent. Antiviral Chem Chemother 1994;5(suppl 1):31-37.
18. [18] Boyd MR, Bacon TH, Sutton D et al. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother 1987;31:1238-1242.
19. [19] Vere Hodge RA, Perkins RM. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother 1989;33:223-229.
20. [20] Earnshaw DL, Bacon TH, Darlison SJ et al. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2 and varicella-zoster virus. Antimicrob Agents Chemother 1992;36:2747-2757.
21. [21] Miller WH, Miller RL. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J Biol Chem 1980;255:7204-7207.
22. [22] Miller WH, Miller RL. Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem Pharmacol 1982;31:3879-3884.
23. [23] Bacon TH, Gilbart J, Howard BA et al. Inhibition of varicella-zoster virus by penciclovir in cell culture and mechanism of action. Antiviral Chem Chemother, in press.
24. [24] Vere Hodge RA. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem Chemother 1993;4:67-84.
25. [25] Larsson A, Stenberg K, Ericson A-C et al. Mode of action, toxicity, pharmacokinetics and efficacy of some new antiherpesvirus guanosine analogs related to buciclovir. Antimicrob Agents Chemother, 1986;30:598-605.
26. [26] Datema R, Ericson A-C, Field HJ et al. Critical determinants of antiherpes efficacy of buciclovir and related acyclic guanosine analogs. Antiviral Res, 1987;7:303-316.
27. [27] Lowe, D.M., Alderton, W.K., Ellis, M.R. et al. Mode of action of (R)-9[4-hydroxy-2-(hydroxymethyl)butyl]guanosine against herpesviruses. Antimicrob Agents Chemother 1995;39:1802-1808.
28. 13C NMR to determine the specificity and absolute configuration of penciclovir phosphate esters formed in HSV-1-and HSV-2-infected cells and by HSV-1-encoded thymidine kinase. Chirality 1993;5: 583-588.
29. [29] Ertl P, Snowden W, Lowe D et al. A comparative study of the in vitro and in vivo antiviral activities of acyclovir and penciclovir. Antiviral Chem Chemother 1995;6:89-97.
30. [30] Korba BE, Boyd MR. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother, in press.
31. [31] Shaw T, Amor P, Civitico G et al. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother 1994;38:719-723.
32. [32] Ueda K, Tsurimoto T, Nagahata T et al. An in vitro system for screening anti-hepatitis B virus drugs. Virology 1989;169: 213-216.
33. [33] Mok SS, Shaw T, Locarnini S. Preferential inhibition of human hepatitis B virus (HBV) DNA polymerase by the (R)-enantiomer of penciclovir triphosphate. Abstract H66:191, 35th ICAAC, San Francisco, CA, 17-20 September 1995.
34. [34] Seeger C, Summers J, Mason WS. Viral DNA synthesis. Curr Topics Microbiol Immunol 1991;168:41-60.
35. [35] Keller PM, McKee SA, Fyfe JA. Cytoplasmic 5′-nucleotidase catalyzes acyclovir phosphorylation. J Biol Chem 1985;260: 8664-8667.
36. [36] Itoh R. IMP-GMP 5′-nucleotidase. Comp Biochem Physiol 1993;105B:13-19.
37. [37] Ilsley DD, Lee S-H, Miller WH et al. Acyclic guanosine analogs inhibit DNA polymerases, α, δ and ε with very different potencies and have unique mechanisms of action. Biochemistry 1995;34:2504-2510.
38. [38] Furman PA, St Clair MH, Fyfe JA et al. Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate. J Virol, 1979;32:72-77.
39. [39] Vere Hodge RA, Cheng Y-C. The mode of action of penciclovir. Antiviral Chem Chemother 1993;4(suppl 1):13-24.
40. [40] Reardon JE, Spector T. Herpes simplex virus type 1 DNA polymerase. J Biol Chem, 1989;264:7405-7411.
41. [41] St Clair MH, Richards CA, Spector T et al. 3′-azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 1987;31:1972-1977.
42. [42] Copeland WC, Chen MS, Wang TS-F. Human DNA polymerases α and β are able to incorporate anti-HIV deoxynucleotides into DNA. J Biol Chem 1992;267:21 459-21 464.
43. [43] Richman DD, Fischl MA, Grieco MH et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:192-197.
44. [44] Frank KB, Chiou J-F, Cheng Y-C. Interaction of herpes simplex virus-induced DNA polymerase with 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate. J Biol Chem 1984;259: 1566-1569.
45. [45] Erice A, Jordan MC, Chace BA et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. J Am Med Assoc 1987;257:3082-3087.
46. [46] Darby G. A history of antiherpes research. Antiviral Chem Chemother 1994;5(suppl 1):3-9.
47. [47] Bebault GM, Wall RA, Rennie BA, Sacks SL. Penciclovir (PCV) triphosphate (PCVTP) and acyclovir (ACV) triphosphate (ACVTP) in a human Schwannoma continuous cell line (SW) infected with varicella zoster virus (VZV). Can J Infect Dis 1995;6:287C.
48. [48] Boyd MR, Safrin S, Kern ER. Penciclovir: a review of its spectrum of activity, selectivity and cross-resistance pattern. Antiviral Chem Chemother 1993;4(suppl 1):3-11.
49. [49] Bacon TH, Howard BA, Spender LC, Boyd MR. Activity of penciclovir in antiviral assays against herpes simplex virus. J Antimicrob Chemother, in press.
50. [50] Bacon TH, Howard BA. Further characterisation of the inhibition of herpes simplex virus replication in human cell lines by penciclovir and aciclovir. Antiviral Chem Chemother, in press.
51. [51] Weinberg A, Bate BJ, Masters HB et al. In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2. Antimicrob Agents Chemother 1992;36:2037-2038.
52. [52] Standring-Cox R, Bacon TH, Howard BA. Comparison of a DNA probe assay with the plaque reduction assay for measuring the sensitivity of herpes simplex virus and varicella-zoster virus to penciclovir and acyclovir. J Virol Methods, in press.
53. [53] Harmenberg J, Wahren B, Sundqvist V-A et al. Multiplicity dependence and sensitivity of herpes simplex virus isolates to antiviral compounds. J Antimicrob Chemother 1985;15:567-573.
54. [54] Bacon TH, Boyd MR. Activity of penciclovir against Epstein-Barr virus. Antimicrob Agents Chemother 1995;39:1599-1602.
55. [55] Sutton D, Boyd MR, Tsiquaye K. Evaluation of penciclovir and its oral form, famciclovir against a chronic hepatitis infection in ducks. Abstract 1594:410, 33rd ICAAC, New Orleans, LA, 1993.
56. [56] Tsiquaye KN, Sutton D, Maung M et al. Antiviral activities and pharmacokinetics of penciclovir and famciclovir in Pekin ducks chronically infected with duck hepatitis virus. Antiviral Chem Chemother, in press.
57. [57] Tsiquaye KN, Slomka MJ, Maung M. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. J Med Virol 1994;42:306-310.
58. [58] Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother 1994;38:2454-2457.
59. [59] Bacon TH, Schinazi RF. An overview of the further evaluation of penciclovir against herpes simplex virus and varicella-zoster virus in cell culture highlighting contrasts with acyclovir. Antiviral Chem Chemother 1993;4(suppl 1):25-36.
60. [60] Moore MR, Hamzeh FM, Lee FE-H et al. Activity of (S)-1-(3 hydroxy-2-phosphonylmethoxypropyl)cytosine against human cytomegalovirus when administered as single-bolus dose and continuous infusion in in vitro cell culture perfusion system. Antimicrob Agents Chemother 1994;38:2404-2408.
61. [61] Hamzeh FM, Schaad HJ, Lietman PS. A pharmacokinetic/pharmacodynamic approach for the comparison of penciclovir and acyclovir: utilization of an in vitro model which simulates in vivo pharmacokinetics. Antiviral Res 1995;26(suppl 1):A338.
62. [62] Field A K, Biron KK. 'The end of innocence' revisited: resistance of herpesviruses to antiviral drugs. Clin Microb Rev 1994;7:1-13.
63. [63] Field HJ, Goldthorpe SE. The pathogenicity of drug-resistant variants of herpes simplex virus. Res Virol 1992;143:120-124.
64. [64] Collins P and Ellis MN. Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir. J Med Virol 1993(suppl 1):58-66.
65. [65] Martin JL, Ellis MN, Keller PM et al. Plaque autoradiography assay for the detection and quantitation of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex virus in clinical isolates. Antimicrob Agents Chemother 1985;28:181-187.
66. [66] Ellis MN, Keller PM, Fyfe JA et al. Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity. Antimicrob Agents Chemother 1987;31: 1117-1125.
67. [67] Sacks SL, Wanklin RJ, Reece DE et al. Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? Ann Int Med, 1989;111:893-899.
68. [68] Collins P, Larder BA, Oliver NM et al. Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. J Gen Virol 1989;70:375-382.
69. [69] Kost RG, Hill EL, Tigges M et al. Brief report: Recurrent acyclovir resistant genital herpes in an immunocompetent patient. N Engl J Med 1993;329:1777-1782.
70. [70] Mouly F, Baccard M, Scieux C et al. Chronic recurrent acyclovir-resistant genital herpes in an immunocompetent patient. Dermatology 1995;190:177.
71. [71] Nusinoff Lehrman S, Douglas JM, Corey L et al. Recurrent genital herpes and suppressive oral acyclovir therapy. Ann Int Med 1986;104:786-790.
72. [72] Talarico CL, Phelps WC, Biron KK. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J Virol 1993;67:1024-1033.
73. [73] Chiou HC, Kumura K, Hu A et al. Penciclovir-resistance mutations in the herpes simplex virus DNA polymerase gene. Antiviral Chem Chemother 1995;6:281-288.
74. [74] Boyd MR, Bacon TH, Sutton D. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) in animals. Antimicrob Agents Chemother 1988;32:358-363.
75. [75] Sutton D, Kern ER. Activity of famciclovir and penciclovir in HSV-infected animals: a review. Antiviral Chem Chemother 1993;4(suppl 1):37-46.
76. [76] Field HJ, Tewari D, Sutton D et al. Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model. Antimicrob Agents Chemother 1995;39:1114-1119.
77. [77] Sutton D, Boyd MR. Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16. Antimicrob Agents Chemother 1993;37: 642-645.
78. [78] Ashton RJ, Abbott KH, Smith GM et al. Antiviral activity of famciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16. J Antimicrob Chemother 1994;34:287-290.
79. [79] Goldthorpe SE, Boyd MR, Field HJ. Effects of penciclovir and famciclovir in a murine model of encephalitis induced by intranasal inoculation of herpes simplex virus type 1. Antiviral Chem Chemother 1992;3:37-47.
80. [80] Field HJ, Thackray AM. The effects of delayed-onset chemotherapy using famciclovir or valaciclovir in a murine immunosuppression model for HSV-1. Antiviral Chem Chemother 1995;6:210-216.
81. [81] Field HJ, Thackray AM. Famciclovir and valaciclovir: comparative effects on cutaneous and neurological disease in mice infected with herpes simplex virus type 2. Abstract H105:198, 35th ICAAC, San Francisco, CA, 17-20 September 1995.
82. [82] Thackray AM, Field HJ. Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. J Infect, in press.
83. [83] Lin E, Luscombe C, Wang YY et al. The guanine nucleoside analogue penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother, in press.
84. [84] Main J, Brown JL, Karayianis P et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. Abstract P1 C1/38 S32, European Association for the Study of the Liver, East Hanover, 1994.
85. [85] Schalm SW, de Man RA, Heijtink RA et al. New nucleoside analogues for chronic hepatitis B. J Hepatol 1995;22(suppl 1):52-56.
86. [86] Alexander GJM, Fagan EA, Hegarty JE, Yeo J, Eddleston ALWF, Williams R. Controlled clinical trial of acyclovir in chronic hepatitis B virus infection. J Med Virol 1987;21:81-87.
87. [87] Pagano JS, Sixbey JW, Lin J-C. Acyclovir and Epstein-Barr virus infection. J Antimicrob Chemother 1983;12(suppl B):113-121.
88. [88] Andersson J, Britton S, Ernberg I et al. Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study. J Infect Dis 1986;153:283-290.
89. [89] van der Horst C, Joncas J, Ahronheim G et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. J Infect Dis 1991;164:788-792.
90. [90] Resnick L, Herbst JS, Ablashi DV et al. Regression of oral hairy leukoplakia after orally administered acyclovir therapy. J Am Med Assoc 1988;259:384-388.
91. [91] Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994;4: 241-246.
92. [92] Beutner KR, Friedman DJ, Forszpaniak C et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39:1546-1553.
93. [93] Tyring S, Barbarash RA, Nahik JE et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and post herpetic neuralgia. Ann Int Med 1995;123:89-96.
94. [94] Sacks SL, Varner T, Macintosh M et al. Clinic-initiated treatment of early, culture positive (CP), recurrent genital herpes (RGH) with intravenous (IV) penciclovir (PCV;BRL 39123A) vs placebo (PLB): clinical benefits of rapid-onset antiviral activity. Abstract 340:155, 31st ICAAC, Chicago, IL, 1991.
95. [95] Sacks SL, Aoki FY, Diaz-Mitoma F et al. Patient-initiated treatment (Tx) of recurrent genital herpes (RGH) with oral famciclovir (FCV): a Canadian multicenter, placebo-controlled, dose-ranging study. Abstract H4:11, 34th ICAAC, Orlando, FL, 4-7 October 1994.
96. [96] Sacks SL, Martel A, Aoki F, Shafran S, St-Pierre C, Lassonde M. Clinic-initiated treatment of recurrent genital herpes using famciclovir: results of a Canadian multicenter study. Abstract 594:198, International Congress for Infectious Disease, Prague, 1994.
97. [97] Mertz GJ, Loveless MO, Kraus SJ et al. Famciclovir for suppression of recurrent genital herpes. Abstract H3:11, 34th ICAAC, Orlando, FL, 4-7 October 1994.
98. [98] Straus SE, Seidlin M, Takiff HE et al. Effect of oral acyclovir treatment on symptomatic and asymptomatic virus shedding in recurrent genital herpes. Sex Transm Dis 1988;16:107-113.